Cytokinetics Inc (CYTK) stock

CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/30

$56.13−0.03 (-0.05%)

Close on Nov 13, 2026Market cap $7.80BP/E –Yield –

Cytokinetics statistics

72 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: Feb 23, 2027 (estimated, after the close)
Last ex-dividend date: No dividends
Fundamentals through: Sep 30, 2026
Share price as of: Nov 13, 2026

Valuation ratiosIndustry

Market Cap: $7.80B; $272.32M
Enterprise Value: $6.62B; $146.23M
PS Ratio: 68.88; 3.66

Enterprise valuationIndustry

EV / Sales: 58.45; 2.57

Share statisticsIndustry

Shares Outstanding: 139M; 58M
Shares Change (YoY): 8.57%; 10.8%
Float: 138M; 49M
Shares Held by Insiders: 0.68%; 11.7%
Shares Held by Institutions: 115.4%; 56.4%

Short sellingIndustry

Short Interest: 18M; –
Short Interest Change: -3.75%; -0.80%
Short % of Float: 13.0%; 9.01%
Short % of Shares Outstanding: 12.9%; 6.30%
Days to Cover: 14.15; 5.15

Stock price statisticsIndustry

52-Week High: $88.31; –
52-Week Low: $53.55; –
20-Day Moving Average: $60.11; –
50-Day Moving Average: $64.11; –
200-Day Moving Average: $69.78; –
Average True Range (14): $2.69; –
Price Change (1 Week): 4.54%; -1.15%
Price Change (1 Month): -12.2%; -4.87%
Price Change (3 Months): -26.0%; -21.0%
Price Change (6 Months): -26.0%; -20.6%
Price Change (YTD): -11.7%; -23.6%
Price Change (1 Year): -14.9%; -22.4%
Price Change (3 Years): 63.7%; -29.5%
Price Change (5 Years): 43.2%; -77.9%
Price Change (10 Years): 398.9%; -65.4%
Average Volume (10 Days): 3M; –
Average Volume (20 Days): 2M; –
Average Volume (90 Days): 2M; –
Relative Volume: 0.52; 0.70
Relative Strength Index (14): 38.2; 43.4
Volatility (1 Year): 43.6%; 80.1%
Beta (5 Years): 0.85; 1.07

MarginsIndustry

Operating Margin: -625.2%; -38.7%
Profit Margin: -686.6%; -31.6%
EBITDA Margin: -613.2%; -27.7%
FCF Margin: -519.5%; -9.56%

Returns on capitalIndustry

Return on Assets (ROA): -47.7%; -40.6%
Return on Capital Employed (ROCE): -48.1%; -37.9%

Financial positionIndustry

Current Ratio: 3.36; 3.30
Quick Ratio: 4.62; 2.39

GrowthIndustry

Revenue Growth (YoY): 29.9%; 6.82%
Revenue Growth (3Y CAGR): -2.36%; 2.25%
Revenue Growth (5Y CAGR): 9.54%; 6.41%

EfficiencyIndustry

Asset Turnover: 0.07; 0.40
Revenue Per Employee: $168.34K; $429.29K
Profits Per Employee: -$1.16M; -$689.41K
Employee Count: 673; 74
WACC: 9.16%; 10.2%

Income statement (TTM)Industry

Revenue: $113.29M; $66.37M
Operating Income: -$708.24M; -$21.37M
Net Income: -$777.89M; -$22.35M
EBITDA: -$694.73M; -$17.21M

Balance sheetIndustry

Cash & Short-Term Investments: $1.60B; $68.68M
Total Debt: $418.73M; $116.91M
Net Cash (Debt): $1.18B; $17.76M
Net Cash Per Share: $8.50; $0.80
Equity (Book Value): -$321.17M; $53.89M
Book Value Per Share: -$2.31; $1.50
Tangible Book Value: -$321.17M; $27.13M
Working Capital: $833.73M; $79.99M

Cash flow (TTM)Industry

Operating Cash Flow: -$571.97M; -$12.38M
Capital Expenditures: -$16.61M; -$1.00M
Free Cash Flow: -$588.58M; -$18.21M
FCF Per Share: -$4.23; -$0.42

Dividends and yieldsIndustry

Earnings Yield: -9.97%; -21.8%
FCF Yield: -7.54%; -9.44%

Scores and fair valueIndustry

Altman Z-Score: -1.62; 0.23
Piotroski F-Score: 2; 4

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

Period	CYTK	S&P 500	Difference	CYTK per year	S&P 500 per year
1 month	-8.9%	-3.0%	−5.9 pts
3 months	-23.6%	-2.8%	−20.8 pts
Year to date	-11.7%	+11.5%	−23.2 pts
1 year	-14.3%	+13.5%	−27.8 pts
3 years	+75.4%	+77.7%	−2.3 pts	+20.6%	+21.1%
5 years	+43.2%	+72.6%	−29.4 pts	+7.4%	+11.5%
10 years	+401.2%	+308.2%	+93.0 pts	+17.5%	+15.1%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

18M CYTK shares were sold short on Oct 30, 2026, down 3.7% from the previous report, or 12.98% of the shares available to trade. At recent volumes it would take 14.2 days to buy them back. Over the last 20 sessions, 54.5% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	17,929,635	-3.7%	1,267,044	14.2
Oct 15, 2026	18,628,116	-3.6%	2,138,708	8.7
Sep 30, 2026	19,333,243	+10.6%	2,309,189	8.4
Sep 15, 2026	17,481,383	+0.2%	1,657,464	10.6
Aug 31, 2026	17,442,378	+6.9%	1,792,286	9.7
Aug 14, 2026	16,323,712	+6.7%	2,123,941	7.7
Jul 31, 2026	15,303,504	-10.3%	1,589,679	9.6
Jul 15, 2026	17,051,981	-3.0%	1,897,013	9.0
Jun 30, 2026	17,573,660	+19.0%	3,335,085	5.3
Jun 15, 2026	14,766,477	-4.7%	1,587,014	9.3
May 29, 2026	15,500,865	-5.8%	1,812,301	8.6
May 15, 2026	16,461,785	+3.6%	4,864,393	3.4

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

Where these numbers come from

Parsed from the XBRL in Cytokinetics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-6 reverse split on Jun 25, 2013
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CYTK.

Compare: CYTK vs GYRE · CYTK vs AGIO · CYTK vs GOSS · CYTK vs AKBA · CYTK vs FHTX

Revenue growth29.9% · median 78.0%

Operating margin-625.2% · median -15.7%

Net margin-686.6% · median -33.9%

Company	Revenue	Growth
AKBA	$197.20M	-12.4%
AGIO	$140.84M	+214.4%
CYTK	$113.29M	+29.9%
FHTX	$112.13M	+357.3%
GYRE	$108.15M	-3.7%
GOSS	$78.42M	+78.0%

Company

Next earnings (est.): Feb 23, 2027, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 673
Held by institutions: 100.0%
Auditor: Ernst & Young LLP
SEC CIK: 1061983

Advertisement
300 × 250

See a number that looks wrong?